NEW YORK – The Muscular Dystrophy Association (MDA) has selected Keisha Greaves from Cambridge, Massachusetts, to represent families living with muscular dystrophy and related neuromuscular diseases alongside current National Ambassador eleven-year-old Ethan LyBrand of Decatur, Alabama. “I have been involved with MDA because muscular dystrophy is now a part of me,” said Keisha. “I feel like it is...
Latest News
BUFFALO, NY – A new research paper was published in Genes & Cancer entitled, “Mechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis.” Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer worldwide but is often diagnosed at...
BOSTON, Mass. and KANSAS CITY, Kan. — Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, and its clinical development division Sardocor, together with the University of Kansas Medical Center, today announced the successful treatment of the first patient in the MUSIC-DMD Phase...
ISTANBUL — Zeynep Liva Elmacı, a dystonia patient who has been having uncontrollable involuntary contractions in her legs and arms for the last 5 years, underwent brain pacemaker surgery while awake by watching cartoons. The patient’s surgery was performed Medical Park, Turkey’s health power with 27 Hospitals and thousands of...
Charleston, SC – As the years add up, it’s common to notice slight changes in our ability to remember and think. Older people who have more marked changes than their peers can be diagnosed with mild cognitive impairment (MCI). Currently, we can’t easily predict which of these patients will develop...
TORONTO, Canada and HOUSTON, TX — Medicenna Therapeutics Corp., a clinical-stage immunotherapy company focused on the development of Superkines, today announced initiation of enrollment in the combination arm of the Phase 1/2 ABILITY (ABeta-only IL-2 ImmunoTherapY) study evaluating MDNA11, a long-acting, “beta-enhanced not-alpha” interleukin-2 (IL-2) super-agonist, with Merck’s pembrolizumab (KEYTRUDA®)....
I blog, I tweet and I use Facebook. And as I recently told a medical colleague, social media has been an enormously useful tool in my work. “I can barely keep up with e-mail,” he snorted back. “I’m not about to open up that black box.” About 15 years ago,...
LA JOLLA, Calif. — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in its Phase 2/3 clinical trial, COMBAT-ALS, evaluating MN-166 (ibudilast) for the treatment of...
LA JOLLA, Calif. – MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application...
WINNIPEG, Canada – Medicure Inc. (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that the FDA provides complete approval to enroll patients in its pivotal Phase 3 clinical trial to evaluate the...